The American Journal of Medicine
Volume 120, Issue 1 , Pages 72-82.e3 , January 2007

Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms

  • Russell D. Hull, MBBS, MSc

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Russell D. Hull, MBBS, MSc, Thrombosis Research Unit, 601 South Tower, Foothills Hospital, 1403 29th Street NW, Calgary, Alberta, Canada T2N 2T9.
    • ,
  • Graham F. Pineo, MD

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Rollin F. Brant, PhD

      Affiliations

    • University of British Columbia, Vancouver, BC, Canada
    • ,
  • Andrew F. Mah, BSc

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Natasha Burke, BSc

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Richard Dear, MD

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Turnly Wong, MD

      Affiliations

    • University of Manitoba, Winnipeg, MN, Canada
    • ,
  • Roy Cook, MD

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Susan Solymoss, MD

      Affiliations

    • McGill University, Montreal, PQ, Canada
    • ,
  • Man-Chiu Poon, MD, MSc

      Affiliations

    • University of Calgary, Calgary, AB, Canada
    • ,
  • Gary Raskob, PhD

      Affiliations

    • University of Oklahoma Health Sciences Center, Oklahoma City, Okla.
    • ,
  • LITE Trial Investigators

Received 21 February 2006 ,Accepted 20 March 2006.

References 

  1. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S–193S
  2. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677–681
  3. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682–687
  4. Hull RD, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676–1681
  5. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S–21S
  6. Kearon C, Ginsberg JS, Kovacs M, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–639
  7. Van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonist or low-molecular-weight heparin for the long-term treatment of venous thromboembolism. The Cochrane Database of Systematic Reviews 2002: The Cochrane Library, 2002;(1):CD002001. Available at: www.cochrane.org.
  8. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729–1735
  9. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20:521–526
  10. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999;30:283–290
  11. Hamann H. Lrezidivporphylaxe nach phlebothrombose—orale antikoagulation oder niedermolekulares heparin subkutan [Low molecular with heparin versus coumarin in the prevention of recurrence after deep vein thrombosis]. VASOMED. 1998;10:133–136
  12. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;81:26–31
  13. Lopez-Beret P, Orgaz A, Fonteuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001;33:77–90
  14. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994;72:191–197
  15. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000;84:559–564
  16. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  17. Kher A, Samama MM. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost. 2005;3:473–481
  18. LITE study investigatorsHull RD, Pineo GF, Mah AF, Brant RF. Home-LITE: safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. Thromb Haemost. 2001;(Suppl):OC1647
  19. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaborations. Ann Intern Med. 2001;134:663–694
  20. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987–1991
  21. Ioannidis JPA, Evans SJW, Gotzsche PC, et al. CONSORT Group Better reporting of harms in randomized trials: an extension of the CONSORT Statement. Ann Intern Med. 2004;141:781–788
  22. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:830–831
  23. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med. 1992;152(8):1589–1595
  24. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin nomogram compared with a ‘standard care’ nomogram: a randomized controlled trial. Ann Intern Med. 1993;119:874–881
  25. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S–94S
  26. Lensing AWA, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med. 1989;320:342–345
  27. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997;337:657–662
  28. Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg. 1972;104:134–144
  29. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation. 1983;67:901–906
  30. Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98:891–899
  31. A collaborative study by the PIOPED investigators. Value of the ventilation-perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA. 1990;263:2753–2759
  32. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med. 2000;132:227–232
  33. Dalen JE, Brooks HL, Johnson LW, et al. Pulmonary angiography in acute pulmonary embolism: indications, techniques, and results in 367 patients. Am Heart J. 1971;81:175–185
  34. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855–858
  35. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992;326:975–982
  36. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189–194
  37. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109–1114
  38. Hull RD, Pineo GF, Mah AF, Brant RF LITE Study Investigators. Long-term out-of-hospital treatment with low-molecular weight heparin versus warfarin sodium: a randomized trial comparing the quality of life associated with these antithrombotic therapies. Blood. 2001;98:267A
  39. Hull RD, Pineo GF, Mah AF, Brant RF LITE Study Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy out-of-hospital versus warfarin sodium comparing the post-phlebitic outcomes at three months. Blood. 2001;98:447A
  40. Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526
  41. Bradburn MJ, Deeks JJ, Altman DG. Metan—an alternative meta-analysis command. Stata Tech Bull. 1998;44:4–15
  42. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702
  43. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867–873
  44. Samama CM, Vray M, Barre J, et al. SACRE Study Investigators Extended venous thromboembolism prophylaxis after total hip replacement. Arch Intern Med. 2002;162:2191–2196
  45. Andriuoli G, Mastacchi R, Barnti M, et al. Comparison of the antithrombotic and hemorrhagic effects of heparin and a new low molecular weight heparin in the rat. Haemostasis. 1985;15:324–330
  46. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparins and heparin. Blood. 1982;59:1239–1245
  47. Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost. 2003;89:674–680
  48. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001;111:130–139
  49. Menendez-Jandula B, Souto JC, Oliver A, et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med. 2005;142:1–10
  50. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators Long-term LMWH versus usual-care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119:1062–1072

 The study was supported by a Medical Research Council (now Canadian Institutes for Health Research) and Industry grant (Leo Pharmaceutical Products Ltd A/S of Denmark). Additional funding was provided by Pharmion and Dupont Pharmaceuticals. Leo provided study drug and drug safety monitoring. The funding organization(s) and sponsor(s) did not have a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation or approval of the article.

 Study design table and participating sites appendix available online.

PII: S0002-9343(06)00507-9

doi: 10.1016/j.amjmed.2006.03.030

The American Journal of Medicine
Volume 120, Issue 1 , Pages 72-82.e3 , January 2007

Article Tools

* Image Usage & Resolution